Testing three-drug therapy versus cisplatin for recurrent NPC
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial studies whether gemcitabine plus camrelizumab plus apatinib works better than cisplatin alone for people with recurrent or metastatic non-keratinizing nasopharyngeal cancer. It’s meant for people who haven’t had prior whole-body (systemic) treatment for the returning/spreading cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 70 years old.
- Your cancer is non-keratinizing nasopharyngeal cancer that has returned or spread.
- You haven’t had any whole-body (systemic) treatment for the recurrent/metastatic cancer yet.
- You can do usual activities fairly well (ECOG score 0 or 1) and have a life expectancy over 12 weeks.
- You have at least one measurable tumor on scans (RECIST 1.1).
- Your blood tests and organ function are in an acceptable range for trial treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two types of radiation therapy (standard SBRT and low-dose radiation) along with chemotherapy and an immunotherapy drug (PD-1 antibody) for people whose nasopharyngeal cancer has come back or spread. The goal is to see if this combination can better control the cancer.
This trial tests a new combination of three drugs (TPC, apatinib, and camrelizumab) against the standard two-drug regimen (GP plus camrelizumab) for people with high-risk nasopharyngeal carcinoma that has spread to neck lymph nodes. The goal is to see if the three-drug combination works better and is safe.
This Phase 2 trial tests adding a PD-1 “immunotherapy” medicine (a type of cancer-fighting antibody) along with stereotactic body radiotherapy (very focused radiation) to treat nasopharyngeal cancer that has spread to only a few places. It may help shrink remaining visible spots after initial local radiation and see whether this “consolidation” approach improves control of the cancer.
This trial tests a combination treatment (chemotherapy before, then chemotherapy with radiation) for advanced nasopharyngeal cancer that hasn't spread to distant sites. The goal is to improve survival and control of the disease.
This trial tests a combination of three drugs (MRG003, capecitabine, and a PD-1 inhibitor) for nasopharyngeal cancer that has come back only in the same area. The goal is to see if this combination can shrink the tumor and prevent it from coming back.
This trial tests whether giving chemotherapy plus immunotherapy (pembrolizumab) before and after surgery can help people whose nasopharyngeal cancer has come back in the same area (locally recurrent). The goal is to see if this approach improves outcomes.
Hear when a new Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.